Research programme: noscapine analogues - Cougar Biotechnology

Drug Profile

Research programme: noscapine analogues - Cougar Biotechnology

Latest Information Update: 13 Jul 2009

Price : $50

At a glance

  • Originator Emory University
  • Developer Cougar Biotechnology
  • Class
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jul 2009 Cougar Biotechnology has been acquired by Johnson and Johnson
  • 23 Jul 2007 This programme is still in active development
  • 23 Jun 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top